Scientific Publications

@article{nokey,

title = {Physical enhancement of older adults  using hyperbaric oxygen: a randomized  controlled trial},

author = {Amir Hadanny and Efrat Sasson and Laurian Copel and Malka Daniel-Kotovsky and Eldad Yaakobi and Erez Lang and Gregory Fishlev and Nir Polak and Mony Friedman and Keren Doenyas and Shachar Finci and Yonatan Zemel and Yair Bechor and Shai Efrati},

url = {https://bmcgeriatr.biomedcentral.com/articles/10.1186/s12877-024-05146-3},

year  = {2024},

date = {2024-07-23},

urldate = {2024-07-23},

abstract = {Aging is associated with a progressive decline in the capacity for physical activity. The objective of the current study was to evaluate the effect of an intermittent hyperbaric oxygen therapy (HBOT) protocol on maximal physical performance and cardiac perfusion in sedentary older adults.},

keywords = {Hbot},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Hyperbaric oxygen therapy: future prospects in regenerative therapy and anti-aging},

author = {Gupta M and Rathored J},

url = {https://europepmc.org/article/MED/38757145},

year  = {2024},

date = {2024-05-02},

abstract = {Hyperbaric Oxygen Therapy (HBOT) utilizes 100% oxygen at high atmospheric pressure for clinical applications. HBOT has proven to be an effective supplementary treatment for a variety of clinical and pathological disorders. HBOT's therapeutic results are based on the physiological effects of increased tissue oxygenation, or improved oxygen bioavailability. HBOT's current indications in illnesses like as wound healing, thermal or radiation burns, and tissue necrosis point to its function in facilitating the regeneration process. Various research has revealed that HBOT plays a function in vascularization, angiogenesis, and collagen production augmentation. Individual regeneration capacity is influenced by both environmental and genetic factors. Furthermore, the regenerating ability of different types of tissues varies, and this ability declines with age. HBOT affects physiological processes at the genetic level by altering gene expression, delaying cell senescence, and assisting in telomere length enhancement. The positive results in a variety of indications, ranging from tissue regeneration to better cognitive function, indicate that it has enormous potential in regenerative and anti-aging therapy.},

keywords = {Hbot},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Medical Ozone: A Redox Regulator with Selectivity for Rheumatoid Arthritis Patients},

author = {Olga Sonia León Fernández and Gabriel Takon Oru and Renate Viebahn-Haensler and Gilberto López Cabreja and Irainis Serrano Espinosa and María Elena Corrales Vázquez},

url = {https://europepmc.org/article/MED/38543177},

year  = {2024},

date = {2024-03-19},

abstract = {Rheumatoid arthritis (RA) and osteoarthritis (OA) are the most common arthritic diseases. Medical ozone has demonstrated its effectiveness in combination therapy with methotrexate or non-steroidal anti-inflammatory drugs for RA and OA, respectively. Although RA and OA have been compared from different points of view, few studies have considered their redox status in spite of the oxidative processes that are involved in both diseases. The aim of this study was to compare RA with OA, evaluating their redox status and the effects of ozone on their clinical response to combined therapy with ozone. The redox status of 80 patients was determined: antioxidant defenses, injury markers, two subjective variables (pain and disability), and levels of antibodies against cyclic citrullinated peptides were evaluated. Oxidative stress and clinical response to combined therapy with ozone was higher than in the case of RA. After medical ozone treatment, there was an increase in antioxidant defense and a decrease in injury markers as well as pain, disability, and autoantibody concentrations. Redox biomarkers were able to differentiate between both arthritic diseases and combined therapy with ozone (methotrexate + ozone), showing a therapeutic selectivity for RA in comparison with OA.},

keywords = {Ozone Therapy},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {How Ozone Applications in the Blood Can Influence Clinical Therapy Success via the Modulation of Cell Biology and Immunity},

author = {Salvatore Chirumbolo and Luigi Valdenassi and Umberto Tirelli and Giovanni Ricevuti and Sergio Pandolfi and Francesco Vaiano and Antonio Galoforo and Fortunato Loprete and Vincenzo Simonetti and Marianna Chierchia and Debora Bellardi and Tommaso Richelmi and Marianno Franzini},

url = {https://www.mdpi.com/2079-7737/12/12/1512},

year  = {2023},

date = {2023-12-11},

abstract = {Background. Ozone is an allotrope of oxygen whose use in medicine has rapidly grown in recent years. Ozonated blood allows for the use of ozone in a safe modality, as plasma and blood cells are endowed with an antioxidant system able to quench ozone’s pro-oxidant property and to elicit the Nrf2/Kwap1/ARE pathway. Methods. We present two clinical studies, a case-series (six patients) observational study adopting ozone as a major autohemotherapy and topical ozone to address infected post-surgical wounds with multi-drug resistant bacteria and an observational study (250 patients) using ozonated blood for treating knee osteoarthritis. Results. Ozonated blood via major autohemotherapy reduced the extent of infections in wounds, reduced the inflammatory biomarkers by more than 75% and improved patients’ QoL, whereas ozonated blood via minor autohemotherapy improved significantly (p < 0.001) WOMAC and Lequesne’s parameters in knee osteoarthritis. Conclusions. The models described, i.e., ozone autohemotherapy in wound antimicrobial treatment and ozonated blood in knee osteoarthrosis, following our protocols, share the outstanding ability of ozone to modulate the innate immune response and address bacterial clearance as well as inflammation and pain.},

keywords = {Ozone Therapy},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Exploring the Potential of Stem Cell-Based Therapy for Aesthetic and Plastic Surgery},

author = {Dang-Khoa Tran and Thuy Nguyen and Thi Phuong and Nhat-Le Bui and Vijai Singh and Qi Hao Looi},

url = {https://doi.org/10.1109/RBME.2021.3134994},

doi = {https://doi.org/10.1109/RBME.2021.3134994},

year  = {2023},

date = {2023-01-05},

urldate = {2023-01-05},

abstract = {Over the last decade, stem cell-associated therapies are widely used because of their potential in self-renewable and multipotent differentiation ability. Stem cells have become more attractive for aesthetic uses and plastic surgery, including scar reduction, breast augmentation, facial contouring, hand rejuvenation, and anti-aging. The current preclinical and clinical studies of stem cells on aesthetic uses also showed promising outcomes. Adipose-derived stem cells are commonly used for fat grafting that demonstrated scar improvement, anti-aging, skin rejuvenation properties, etc. While stem cell-based products have yet to receive approval from the FDA for aesthetic medicine and plastic surgery. Moving forward, the review on the efficacy and potential of stem cell-based therapy for aesthetic and plastic surgery is limited. In the present review, we discuss the current status and recent advances of using stem cells for aesthetic and plastic surgery. The potential of cell-free therapy and tissue engineering in this field is also highlighted. The clinical applications, advantages, and limitations are also discussed. This review also provides further works that need to be investigated to widely apply stem cells in the clinic, especially in aesthetic and plastic contexts.},

keywords = {Anti-Aging},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Mesenchymal Stem Cell-Derived Exosomes and Intervertebral Disc Regeneration Review},

author = {Bhujel B and Shin HE and Choi DJ and Han I},

url = {https://europepmc.org/article/MED/35806304},

doi = {https://europepmc.org/article/MED/35806304},

year  = {2022},

date = {2022-06-30},

urldate = {2022-06-30},

abstract = {Intervertebral disc degeneration (IVDD) is a common cause of lower back pain (LBP), which burdens individuals and society as a whole. IVDD occurs as a result of aging, mechanical trauma, lifestyle factors, and certain genetic abnormalities, leads to loss of nucleus pulposus, alteration in the composition of the extracellular matrix, excessive oxidative stress, and inflammation in the intervertebral disc. Pharmacological and surgical interventions are considered a boon for the treatment of IVDD, but the effectiveness of those strategies is limited. Mesenchymal stem cells (MSCs) have recently emerged as a possible promising regenerative therapy for IVDD due to their paracrine effect, restoration of the degenerated cells, and capacity for differentiation into disc cells. Recent investigations have shown that the pleiotropic effect of MSCs is not related to differentiation capacity but is mediated by the secretion of soluble paracrine factors. Early studies have demonstrated that MSC-derived exosomes have therapeutic potential for treating IVDD by promoting cell proliferation, tissue regeneration, modulation of the inflammatory response, and reduced apoptosis. This paper highlights the current state of MSC-derived exosomes in the field of treatment of IVDD with further possible future developments, applications, and challenges.},

keywords = {Spine Conditions, U-MSC Stem cells research},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Advances in Stem Cell Therapies for Rotator Cuff Injuries},

author = {Hao-Nan Wang and Xiao Rong and Lu-Ming Yang and Wei-Zhong Hua and Guo-Xin Nicorresponding},

url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174670/},

year  = {2022},

date = {2022-05-25},

abstract = {Rotator cuff injury is a common upper extremity musculoskeletal disease that may lead to persistent pain and functional impairment. Despite the clinical outcomes of the surgical procedures being satisfactory, the repair of the rotator cuff remains problematic, such as through failure of healing, adhesion formation, and fatty infiltration. Stem cells have high proliferation, strong paracrine action, and multiple differentiation potential, which promote tendon remodeling and fibrocartilage formation and increase biomechanical strength. Additionally, stem cell-derived extracellular vesicles (EVs) can increase collagen synthesis and inhibit inflammation and adhesion formation by carrying regulatory proteins and microRNAs. Therefore, stem cell-based therapy is a promising therapeutic strategy that has great potential for rotator cuff healing. In this review, we summarize the advances of stem cells and stem cell-derived EVs in rotator cuff repair and highlight the underlying mechanism of stem cells and stem cell-derived EVs and biomaterial delivery systems. Future studies need to explore stem cell therapy in combination with cellular factors, gene therapy, and novel biomaterial delivery systems.},

keywords = {Joint Pain, Sports Injuries},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Mesenchymal Stem Cells From Different Sources in Meniscus Repair and Regeneration},

author = {Guocheng Ding and Jianing Du and Xiaoqing Hu and Yingfang},

url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091333/},

year  = {2022},

date = {2022-04-27},

urldate = {2022-04-27},

abstract = {Meniscus damage is a common trauma that often arises from sports injuries or menisci tissue degeneration. Current treatment methods focus on the repair, replacement, and regeneration of the meniscus to restore its original function. The advance of tissue engineering provides a novel approach to restore the unique structure of the meniscus. Recently, mesenchymal stem cells found in tissues including bone marrow, peripheral blood, fat, and articular cavity synovium have shown specific advantages in meniscus repair. Although various studies explore the use of stem cells in repairing meniscal injuries from different sources and demonstrate their potential for chondrogenic differentiation, their meniscal cartilage-forming properties are yet to be systematically compared. Therefore, this review aims to summarize and compare different sources of mesenchymal stem cells for meniscal repair and regeneration.},

keywords = {Joint Pain, Sports Injuries},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Stem cell therapy for COVID-19 pneumonia},

author = {Maziar Malekzadeh Kebria and Peiman Brouki Milan and Noshad Peyravian and Jafar Kiani and Soheil Khatibi and Masoud Mozafari},

url = {https://link.springer.com/article/10.1186/s43556-021-00067-8},

year  = {2022},

date = {2022-02-17},

urldate = {2022-02-17},

abstract = {Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus is a highly contagious microorganism, and despite substantial investigation, no progress has been achieved in treating post-COVID complications. However, the virus has made various mutations and has spread around the world. Researchers have tried different treatments to reduce the side effects of the COVID-19 symptoms. One of the most common and effective treatments now used is steroid therapy to reduce the complications of this disease. Long-term steroid therapy for chronic inflammation following COVID-19 is harmful and increases the risk of secondary infection, and effective treatment remains challenging owing to fibrosis and severe inflammation and infection. Sometimes our immune system can severely damage ourselves in disease. In the past, many researchers have conducted various studies on the immunomodulatory properties of stem cells. This property of stem cells led them to modulate the immune system of autoimmune diseases like diabetes, multiple sclerosis, and Parkinson's. Because of their immunomodulatory properties, stem cell-based therapy employing mesenchymal or hematopoietic stem cells may be a viable alternative treatment option in some patients. By priming the immune system and providing cytokines, chemokines, and growth factors, stem cells can be employed to build a long-term regenerative and protective response. This review addresses the latest trends and rapid progress in stem cell treatment for Acute Respiratory Distress Syndrome (ARDS) following COVID-19.},

keywords = {Pulmonary Disease},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Human mesenchymal stem cells treatment for severe COVID-19},

author = {Lei Shi and Xin Yuan and Weiqi Yao and Siyu Wang and Chao Zhang and Bo Zhang and Jinwen Song and Lei Huang and Zhe Xu},

url = {https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00583-1/fulltext},

year  = {2021},

date = {2021-12-25},

abstract = {The long-term consequences of human umbilical cord-derived mesenchymal stem cell (UC-MSC) treatment for COVID-19 patients are yet to be reported. This study assessed the 1-year outcomes in patients with severe COVID-19, who were recruited in our previous UC-MSC clinical trial.

Methods



In this prospective, longitudinal, cohort study, 100 patients enrolled in our phase 2 trial were prospectively followed up at 3-month intervals for 1 year to evaluate the long-term safety and effectiveness of UC-MSC treatment. The primary endpoint was an altered proportion of whole-lung lesion volumes measured by high-resolution CT. Other imaging outcomes, 6 min walking distance (6-MWD), lung function, plasma biomarkers, and adverse events were also recorded and analyzed. This trial was registered with ClinicalTrials.gov (NCT04288102).

Findings



MSC administration improved in whole-lung lesion volume compared with the placebo with a difference of −10.8% (95% CI: −20.7%, −1.5%, p = 0.030) on day 10. MSC also reduced the proportion of solid component lesion volume compared with the placebo at each follow-up point. More interestingly, 17.9% (10/56) of patients in the MSC group had normal CT images at month 12, but none in the placebo group (p = 0.013). The incidence of symptoms was lower in the MSC group than in the placebo group at each follow-up time. Neutralizing antibodies were all positive, with a similar median inhibition rate (61.6% vs. 67.6%) in both groups at month 12. No difference in adverse events at the 1-year follow-up and tumor markers at month 12 were observed between the two groups.},

keywords = {Pulmonary Disease},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Hyperbaric oxygen therapy induces transcriptome changes in elderly: a prospective trial.},

author = {Hadanny A and Forer R and Volodarsky D and Daniel-Kotovsky M and Catalogna M and Zemel Y and Bechor Y and and Efrati S.},

url = {https://europepmc.org/article/MED/34818212},

year  = {2021},

date = {2021-11-24},

abstract = {Aging is characterized by the progressive loss of physiological capacity. Changes in gene expression can alter activity in defined age-related molecular pathways leading to cellular aging and increased aging disease susceptibility. The aim of the current study was to evaluate whether hyperbaric oxygen therapy (HBOT) affects gene expression in normal, non-pathological, aging adults.},

keywords = {Hbot},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Potential for Stem Cell-Based Therapy in the Road of Treatment for Neurological Disorders Secondary to COVID-19},

author = {Babak Arjmand and Peyvand Parhizkar Roudsari and Sepideh Alavi-Moghadam and Mostafa Rezaei-Tavirani and Akram Tayanloo-Beik and Neda Mehrdad and Hossein Adibi and Bagher Larijani },

url = {https://link.springer.com/article/10.1007/s40883-021-00234-x},

year  = {2021},

date = {2021-10-29},

abstract = {The severe acute respiratory syndrome coronavirus 2 has led to the worldwide pandemic named coronavirus disease 2019 (COVID-19). It has caused a significant increase in the number of cases and mortalities since its first diagnosis in December 2019. Although COVID-19 primarily affects the respiratory system, neurological involvement of the central and peripheral nervous system has been also reported. Herein, the higher risk of neurodegenerative diseases in COVID-19 patients in future is also imaginable. Neurological complications of COVID-19 infection are more commonly seen in severely ill individuals; but, earlier diagnosis and treatment can lead to better long-lasting results. In this respect, stem cell biotechnologies with considerable self-renewal and differentiation capacities have experienced great progress in the field of neurological disorders whether in finding out their underlying processes or proving them promising therapeutic approaches. Herein, many neurological disorders have been found to benefit from stem cell medicine strategies. Accordingly, in the present review, the authors are trying to discuss stem cell-based biotechnologies as promising therapeutic options for neurological disorders secondary to COVID-19 infection through reviewing neurological manifestations of COVID-19 and current stem cell-based biotechnologies for neurological disorders.},

keywords = {Neurological Conditions, Pulmonary Disease},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Mesenchymal Stem Cell-derived Small Extracellular Vesicles Mitigate Oxidative Stress-induced Senescence in Endothelial Cells},

author = {Xiao X and Xu M and Yu H and Wang L and Li X and Rak J and Wang S and Zhao RC},

url = {https://doi.org/10.1038/s41392-021-00765-3},

doi = {https://doi.org/10.1038/s41392-021-00765-3},

year  = {2021},

date = {2021-10-21},

urldate = {2021-10-21},

abstract = {Senescent endothelial cells (ECs) could impair the integrity of the blood vessel endothelium, leading to vascular aging and a series of diseases, such as atherosclerosis, diabetes. Preventing or mitigating EC senescence might serve as a promising therapeutic paradigm for these diseases. Recent studies showed that small extracellular vesicles (sEV) have the potential to transfer bioactive molecules into recipient cells and induce phenotypic changes. Since mesenchymal stem cells (MSCs) have long been postulated as an important source cell in regenerative medicine, herein we investigated the role and mechanism of MSC-derived sEV (MSC-sEV) on EC senescence. In vitro results showed that MSC-sEV reduced senescent biomarkers, decreased senescence-associated secretory phenotype (SASP), rescued angiogenesis, migration and other dysfunctions in senescent EC induced by oxidative stress. In the In vivo natural aging and type-2 diabetes mouse wound-healing models (both of which have senescent ECs), MSC-sEV promoted wound closure and new blood vessel formation. Mechanically, miRNA microarray showed that miR-146a was highly expressed in MSC-sEV and also upregulated in EC after MSC-sEV treatment. miR-146a inhibitors abolished the stimulatory effects of MSC-sEV on senescence. Moreover, we found miR-146a could suppress Src phosphorylation and downstream targets VE-cadherin and Caveolin-1. Collectively, our data indicate that MSC-sEV mitigated endothelial cell senescence and stimulate angiogenesis through miR-146a/Src.},

keywords = {Anti-Aging},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Effects of Mesenchymal Stem Cell-Derived Exosomes on Autoimmune Diseases},

author = {Ziwei Shen and Wei Huang and Jun Liu and Jie Tian and Shengjun Wang and Ke Rui},

url = {https://doi.org/10.3389/fimmu.2021.749192},

year  = {2021},

date = {2021-09-21},

urldate = {2021-09-21},

abstract = {Recent years, the immunosuppressive properties of mesenchymal stem cells (MSCs) have been demonstrated in preclinical studies and trials of inflammatory and autoimmune diseases. Emerging evidence indicates that the immunomodulatory effect of MSCs is primarily attributed to the paracrine pathway. As one of the key paracrine effectors, mesenchymal stem cell-derived exosomes (MSC-EXOs) are small vesicles 30-200 nm in diameter that play an important role in cell-to-cell communication by carrying bioactive substances from parental cells. Recent studies support the finding that MSC-EXOs have an obvious inhibitory effect toward different effector cells involved in the innate and adaptive immune response. Moreover, substantial progress has been made in the treatment of autoimmune diseases, including multiple sclerosis (MS), systemic lupus erythematosus (SLE), type-1 diabetes (T1DM), uveitis, rheumatoid arthritis (RA), and inflammatory bowel disease (IBD). MSC-EXOs are capable of reproducing MSC function and overcoming the limitations of traditional cell therapy. Therefore, using MSC-EXOs instead of MSCs to treat autoimmune diseases appears to be a promising cell-free treatment strategy. In this review, we review the current understanding of MSC-EXOs and discuss the regulatory role of MSC-EXOs on immune cells and its potential application in autoimmune diseases.},

keywords = {Autoinmune Disorders},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Effects of Mesenchymal Stem Cell-Derived Exosomes on Autoimmune Diseases},

author = {Ziwei Shen and Wei Huang and Jun Liu and Jie Tian and Shengjun Wang and Ke Rui},

url = {https://doi.org/10.3389/fimmu.2021.749192},

year  = {2021},

date = {2021-09-21},

urldate = {2021-09-21},

abstract = {Recent years, the immunosuppressive properties of mesenchymal stem cells (MSCs) have been demonstrated in preclinical studies and trials of inflammatory and autoimmune diseases. Emerging evidence indicates that the immunomodulatory effect of MSCs is primarily attributed to the paracrine pathway. As one of the key paracrine effectors, mesenchymal stem cell-derived exosomes (MSC-EXOs) are small vesicles 30-200 nm in diameter that play an important role in cell-to-cell communication by carrying bioactive substances from parental cells. Recent studies support the finding that MSC-EXOs have an obvious inhibitory effect toward different effector cells involved in the innate and adaptive immune response. Moreover, substantial progress has been made in the treatment of autoimmune diseases, including multiple sclerosis (MS), systemic lupus erythematosus (SLE), type-1 diabetes (T1DM), uveitis, rheumatoid arthritis (RA), and inflammatory bowel disease (IBD). MSC-EXOs are capable of reproducing MSC function and overcoming the limitations of traditional cell therapy. Therefore, using MSC-EXOs instead of MSCs to treat autoimmune diseases appears to be a promising cell-free treatment strategy. In this review, we review the current understanding of MSC-EXOs and discuss the regulatory role of MSC-EXOs on immune cells and its potential application in autoimmune diseases.},

keywords = {Autoinmune Disorders},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Stem cells and regenerative medicine in sport science},

author = {Claire E. Stewart},

year  = {2021},

date = {2021-08-27},

abstract = {The estimated cost of acute injuries in college-level sports in the USA is ∼1.5 billion dollars annually, without considering the cost of follow-up rehabilitation. In addition to this huge financial burden, sports injuries may be career-ending for some athletes without appropriate diagnosis and relevant interventions. With a growing number of females participating in contact-based and pivoting sports, middle-aged individuals returning to sports,s and natural injuries of aging all increasing, such costs and negative implications for quality of life will expand. For those injuries that cannot be predicted and prevented, there is a real need to optimize repair, recovery, and function post-injury in the sporting and clinical worlds. The 21st century has seen rapid growth in regenerative medicine for sporting injuries to progress recovery and facilitate return to sport. Such interventions harness knowledge relating to stem cells as a potential for injury repair. While the field is rapidly growing, consideration beyond the stem cells to the factors they secrete should be considered in developing practical, affordable treatments.},

keywords = {Sports Injuries},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Stem Cells and Exosomes: New Therapies for Intervertebral Disc Degeneration},

author = {Zoe Krut and Gadi Pelled and Dan Gazit and Zulma Gazit},

url = {https://doi.org/10.3390/cells10092241},

doi = {https://doi.org/10.3390/cells10092241},

year  = {2021},

date = {2021-08-20},

urldate = {2021-08-20},

abstract = {Intervertebral disc degeneration (IVDD) occurs as a result of an imxbalance of the anabolic and catabolic processes in the intervertebral disc, leading to an alteration in the composition of the extracellular matrix (ECM), loss of nucleus pulposus (NP) cells, excessive oxidative stress and inflammation. Degeneration of the IVD occurs naturally with age, but mechanical trauma, lifestyle factors and certain genetic abnormalities can increase the likelihood of symptomatic disease progression. IVDD, often referred to as degenerative disc disease (DDD), poses an increasingly substantial financial burden due to the aging population and increasing incidence of obesity in the United States. Current treatments for IVDD include pharmacological and surgical interventions, but these lack the ability to stop the progression of disease and restore the functionality of the IVD. Biological therapies have been evaluated but show varying degrees of efficacy in reversing disc degeneration long-term. Stem cell-based therapies have shown promising results in the regeneration of the IVD, but face both biological and ethical limitations. Exosomes play an important role in intercellular communication, and stem cell-derived exosomes have been shown to maintain the therapeutic benefit of their origin cells without the associated risks. This review highlights the current state of research on the use of stem-cell derived exosomes in the treatment of IVDD.},

keywords = {Spine Conditions},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Stem cell therapies in tendon-bone healing},

author = {Yue Xu and Wan-Xia Zhang and Li-Na Wang and Yue-Qing Ming and Yu-Lin Li and Guo-Xin Ni},

url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316867/},

year  = {2021},

date = {2021-07-26},

abstract = {Tendon-bone insertion injuries such as rotator cuff and anterior cruciate ligament injuries are currently highly common and severe. The key method of treating this kind of injury is the reconstruction operation. The success of this reconstructive process depends on the ability of the graft to incorporate into the bone. Recently, there has been substantial discussion about how to enhance the integration of tendon and bone through biological methods. Stem cells like bone marrow mesenchymal stem cells (MSCs), tendon stem/progenitor cells, synovium-derived MSCs, adipose-derived stem cells, or periosteum-derived periosteal stem cells can self-regenerate and potentially differentiate into different cell types, which have been widely used in tissue repair and regeneration. Thus, we concentrate in this review on the current circumstances of tendon-bone healing using stem cell therapy.},

keywords = {Joint Pain, Sports Injuries},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Hyperbaric oxygen therapy increases telomere length and decreases immunosenescence in isolated blood cells},

author = {Hachmo Y and Hadanny A and Abu Hamed R and Daniel-Kotovsky M and Catalogna M and Fishlev G and Lang E and Polak N and Doenyas K and Friedman M and Zemel Y and Bechor Y and Efrati S.},

url = {https://europepmc.org/article/MED/33206062},

year  = {2020},

date = {2020-11-18},

abstract = {Aging is characterized by the progressive loss of physiological capacity. At the cellular level, two key hallmarks of the aging process include telomere length (TL) shortening and cellular senescence. Repeated intermittent hyperoxic exposures, using certain hyperbaric oxygen therapy (HBOT) protocols, can induce regenerative effects which normally occur during hypoxia. The aim of the current study was to evaluate whether HBOT affects TL and senescent cell concentrations in a normal, non-pathological, aging adult population.},

keywords = {Hbot},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Current advances in stem cell-based therapies for hair regeneration},

author = {An-Ran Yuan and Qiong Bian and Jian-Qing Gao},

url = {https://doi.org/10.1016/j.ejphar.2020.173197},

year  = {2020},

date = {2020-08-15},

abstract = {Alopecia is resulted from various factors that can decrease the regeneration capability of hair follicles and affect hair cycles. This process can be devastating physically and psychologically. Nevertheless, the available treatment strategies are limited, and the therapeutic outcomes are not satisfactory. According to the possible pathogenesis of nonscarring alopecia, especially androgenetic alopecia, recovering or replenishing the signals responsible for hair follicle stem cells activation is a promising strategy for hair regeneration. Recently, stem cell-based therapies, especially those based on the stem cell-derived conditioned medium (CM), which is secreted by stem cells and is rich in paracrine factors, have been widely explored as the hair regenerative medicine. Several studies have focused on altering the composition and up-regulating the amount of secretome of the stem cells, thereby enhancing its therapeutic effects. Besides, stem cell-derived exosomes, which are present in the CM as message entities, are also promising for hair regrowth. In this review, the up-to-date progress of research efforts focused on stem cell-based therapies for hair regeneration will be discussed, including their therapeutic potentials with respective merits and demerits, as well as the possible mechanisms.},

keywords = {Hair loss},

pubstate = {published},

tppubtype = {article}

}